Top Markets
#1 DogBull DogBull +107.63%
#2 ADO Protocol ADO Protocol +51.91%
#3 Siacoin Siacoin +50.76%
#4 The Bitcoin Bull The Bitcoin Bull +44.24%
#5 MarsCoin MarsCoin +41.20%
#6 Ontology Gas Ontology Gas +23.42%
#7 Nockchain Nockchain +20.36%
#8 Apertum Apertum +20.22%
#9 UnifAI Network UnifAI Network +18.93%
#10 Falcon Finance Falcon Finance +16.52%
Coin of the day
DogBull DogBull
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Rang in aandelen #15662
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Aandeelprijs
$0.63963115
Laatst gesynchroniseerd: 2026-08-26
Marktkapitalisatie
$339.16M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-35.23%
Land
CN
Handel Jiangsu Recbio Technology Co., Ltd. (2179)

Categorie

Healthcare
Koersgeschiedenis voor Jiangsu Recbio Technology Co., Ltd. (2179)
Hoogste slotkoers: $0.64 op 2026-08-01

Laagste slotkoers: $3.22 op 2022-03-01
Koersgeschiedenis van Jiangsu Recbio Technology Co., Ltd. van 2022 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) 4.07%
2025 -37.60%
2024 -16.16%
2023 -55.93%
2022 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.82 40.36%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.65%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.37 -11.93%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $147.48 512.20%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $748.60 4.92%
CH